Department of Pharmacology, University of Minnesota, Minneapolis, MN 55455, USA.
Genes (Basel). 2024 Jan 10;15(1):85. doi: 10.3390/genes15010085.
DNA-protein crosslinks (DPCs) represent a unique and complex form of DNA damage formed by covalent attachment of proteins to DNA. DPCs are formed through a variety of mechanisms and can significantly impede essential cellular processes such as transcription and replication. For this reason, anti-cancer drugs that form DPCs have proven effective in cancer therapy. While cells rely on numerous different processes to remove DPCs, the molecular mechanisms responsible for orchestrating these processes remain obscure. Having this insight could potentially be harnessed therapeutically to improve clinical outcomes in the battle against cancer. In this review, we describe the ways cells enzymatically process DPCs. These processing events include direct reversal of the DPC via hydrolysis, nuclease digestion of the DNA backbone to delete the DPC and surrounding DNA, proteolytic processing of the crosslinked protein, as well as covalent modification of the DNA-crosslinked proteins with ubiquitin, SUMO, and Poly(ADP) Ribose (PAR).
DNA-蛋白质交联物(DPCs)代表了一种独特而复杂的 DNA 损伤形式,是通过蛋白质与 DNA 的共价连接形成的。DPCs 通过多种机制形成,并可能严重阻碍转录和复制等基本细胞过程。出于这个原因,形成 DPCs 的抗癌药物已被证明在癌症治疗中有效。虽然细胞依赖于许多不同的过程来去除 DPCs,但负责协调这些过程的分子机制仍然不清楚。如果能够深入了解这些机制,就有可能在治疗上加以利用,以改善对抗癌症的临床结果。在这篇综述中,我们描述了细胞通过酶促反应处理 DPCs 的方式。这些处理事件包括通过水解直接逆转 DPC、通过核酸内切酶消化 DNA 骨架以删除 DPC 和周围的 DNA、交联蛋白的蛋白水解处理,以及用泛素、SUMO 和聚(ADP-核糖)(PAR)对 DNA-交联蛋白进行共价修饰。